Kintsugi(US) | $6,000,000 | (May 31, 2024)
Valar Labs | $22,000,000 | (May 31, 2024)
Plural Energy | $2,330,000 | (May 31, 2024)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
HoundDog.ai | $3,100,000 | (May 31, 2024)
Fortunafi | $9,500,000 | (May 31, 2024)
Faircado | $3,252,930 | (May 31, 2024)
Basalt Tech | $3,500,000 | (May 31, 2024)
FintechOS | $60,000,000 | (May 31, 2024)
Remark | $10,300,000 | (May 31, 2024)
Revive | $3,500,000 | (May 31, 2024)
Viable(UK) | $3,100,000 | (May 31, 2024)
Weave | $10,000,000 | (May 31, 2024)